Adiponectin inhibits hepatic stellate cell (HSC) activation and subsequent development of liver fibrosis via multiple mechanisms. Phosphatase and tensin homolog deletion 10 (PTEN) plays a crucial role in suppression of HSC activation, but its regulation by adiponectin is not fully understood. Here, we investigated the effect of adiponectin on PTEN in LX-2 cells, a human cell line and examined the underlying molecular mechanisms involved in adiponectin-mediated upregulation of PTEN activity during fibrosis. PTEN expression was found to be significantly reduced in the livers of mice treated with CCl 4 , whereas its expression was rescued by adiponectin treatment. The DNA methylation proteins DNMT1, DNMT3A, and DNMT3B are all highly expressed in activated primary HSCs compared to quiescent HSCs, and thus represent additional regulatory targets during liver fibrogenesis. Expression of DNMT proteins was significantly induced in the presence of fibrotic stimuli; however, only DNMT3B expression was reduced in the presence of adiponectin. Adiponectin-induced suppression of DNMT3B was found to be mediated by enhanced miR-29b expression. Furthermore, PTEN expression was significantly increased by overexpression of miR-29b, whereas its expression was markedly reduced by a miR-29b inhibitor in LX-2 cells. These findings suggest that adiponectin-induced upregulation of miR-29b can suppress DNMT3B transcription in LX-2 cells, thus resulting in reduced methylation of PTEN CpG islands and ultimately suppressing the PI3K/AKT pathway. Together, these data suggest a possible new explanation for the inhibitory effect of adiponectin on HSC activation and liver fibrogenesis.
Introduction
Hepatic fibrosis is a reversible wound-healing process characterized by excessive deposition of extracellular matrix (ECM) proteins, especially fibrillar collagen [1, 2] . Fibrosis is a consequence of chronic injury associated with alcoholic liver disease (ALD), non-alcoholic fatty liver disease (NAFLD) as well as chronic viral diseases such as hepatitis C viral infection [3, 4] . Hepatic stellate cells (HSCs) are the primary players in hepatic fibrosis development and progression [5] . When activated, HSCs transdifferentiate into α-smooth muscle actin (α-SMA) expressing myofibroblast-like cells, which are the major matrixproducing cells involved in hepatic fibrosis [1] . We and others have recently demonstrated that adiponectin, a 30 kDa adipocytokine primarily secreted by white adipose tissue (WAT), has anti-fibrotic properties both in vivo and in vitro [6] [7] [8] [9] [10] . Adiponectin signaling occurs via its two cognate receptors: adiponectin receptor 1 and 2 [11, 12] . However, the molecular mechanism responsible for anti-fibrotic effects induced by adiponectin remained unexplored.
The phosphatase and tensin homolog deleted on chromosome 10 (PTEN) is a dual phosphatase, and its major function is to dephosphorylate phosphatidylinositol 3, 4, 5-triphosphate (PIP3) to phosphatidylinositol 4, 5-bisphosphate [13] . Decreased PTEN expression has been reported in fibrotic diseases of the lungs, heart, skin as well as liver [14] [15] [16] [17] [18] . Specifically, deletion of the Pten gene in mice results in excess deposition of type I collagen, while PTEN overexpression can reverse chemical-induced liver fibrosis [19] . PTEN activity and expression is controlled by several mechanisms including phosphorylation, acetylation, oxidation, ubiquitination, non-coding RNAs, and DNA methylation [20] [21] [22] . For instance, aberrant PTEN promoter methylation is demonstrated in CCl 4 -induced liver fibrosis [23] . DNA methylation is mainly carried out by three highly conserved enzymes, DNMT1, DNMT3A, and DNMT3B [24] .
Recent studies indicate that aberrant microRNA (miRNA) expression is correlated with liver fibrosis [25, 26] . miRNAs are a class of endogenous small non-coding RNAs that are typically 18-22 nucleotides in length [25] . These miRNAs typically work as posttranscriptional regulators of gene expression by binding with a portion of the 3′untranslated-region (3′-UTR) of target mRNAs resulting in degradation or inhibition of the target mRNAs and thus initiation of translation [27] . miRNAs play critical roles in developmental and cellular processes such as growth, differentiation, apoptosis, and oncogenesis [28] .
In the setting of liver fibrosis, miR-19, miR-29, and let-7 overexpression reduce α-SMA and collagen type I expression [29] [30] [31] . Additionally, miR-33a and miR-181b inhibitors reduce collagen type I and α-SMA expression in HSCs [21, 32] . Moreover, published reports demonstrate that PTEN expression is tightly regulated by miR-29b in addition to DNMT3B [33] . However, how adiponectin modulates PTEN promoter methylation and miR-29b expression has not yet been fully described. Here, we hypothesized that adiponectin may play a role as an upstream regulator of PTEN expression via either DNMTs, miR-29b, or both. Hence this study aimed to investigate the molecular mechanisms underlying red solution (Abcam, Cambridge, MA) followed by brief rinses with acetic acid (0.05%). Sections were dehydrated by washing with absolute alcohol. Sections were observed under a light microscope (Axioplan2; Carl Zeiss, Hallbergmoos, Germany). The collagen staining was quantified by using Image J software (NIH, Bethesda).
RNA extraction and qRT-PCR analysis
Total RNA was extracted from liver tissue or LX-2 cells using the RNeasy Mini Kit (Qiagen, Valencia, CA), and one microgram of total RNA was reverse transcribed to cDNA using the Bio-Rad's iScript™ cDNA synthesis kit according to the manufacturer's instructions. Gene expression was measured with real-time PCR using IQ™ SYBR® Green Supermix (Bio-Rad) according to standard protocol. All human and mouse primers were purchased from Sigma-Aldrich (St. Louis, MO, USA). The following primers were used in this study: mouse PTEN (NM_008960): forward 5′-TGGATTCGACTTAGACTTGACCT-3′ and re-verse 5′-GCGGTGTCATAATGTCTCTCAG-3′; mouse DNMT1 (NM_001199433) forward 5′-CCGTGGCTACGAGGAGAAC-3′ and re-verse 5′-CCGTGGCTACGAGGAGAAC-3′; mouse DNMT3A (NM_007872) forward 5′-GATGAGCCTGAGTATGAGGATGG-3′ and reverse 5′-CAAG ACACAATTCGGCCTGG-3′; mouse DNMT3B (NM_001122997) forward 5′-CGTTAATGGGAACTTCAGTGACC-3′ and reverse 5′-CTGCGTGTAAT TCAGAAGGCT-3′; mouse Acta2 (NM_007392) forward 5′-CCCAGACA TCAGGGAGTAATGG-3′ and reverse 5′-TCTATCGGATACTTCAGCG TCA-3′; human PTEN (NM_000314) Forward 5′-TGGATTCGACTTAGA CTTGACCT-3′ and reverse 5′-GGTGGGTTATGGTCTTCAAAAGG-3′. To detect the expression of miR-29b (Accession MIMAT0000100) 5′-CGC TAGCACCATTTGAAATCAG-3′, RT PCR was performed using the Quanta bio microRNA assay (Beverly, MA) according to user manual. The assays were performed in triplicate using the Mastercycler® eprealplex (Eppendorf®), with internal controls (18 s) for the expression of mRNA and U6 for miR-29b. The cycle threshold (Ct) values were normalized to reference gene 18 s/U6 and fold changes in expression were calculated using the 2 −∆∆Ct method.
Cell proliferation assay
Cells were plated at a density of 1 × 10 5 per well in 96-well plates and incubated at 37 °C with 5% CO 2 in a humidified incubator. After 24 h, cells were incubated with 100 μl of CellTiter 96® AQueous One Solution reagent (Promega Corporation, Madison, WI, USA) for an additional 4 h at 37 °C with 5% CO 2 in a humidified incubator. The absorbance at 490 nm was measured on a BioTek Synergy™ 2 plate reader (BioTek Instruments, Inc., Winooski, VT, USA).
Western blot assay
Protein concentration was quantified using a bicinchoninic acid (BCA) protein assay kit (ThermoFisher, Waltham, MA) and boiled in 1× Lamellae buffer (Bio-Rad) for 5 min in a heat block. Ten to thirty micrograms of total protein was subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and then transferred to 0.45 μm nitrocellulose membrane. The membranes were incubated with 5% non-fat dry milk followed by incubation with the primary antibody (1:1000) in 5% BSA for overnight at 4 °C. The membranes were washed with Tris-buffered saline tween followed by incubation with horse-radish peroxide-conjugated secondary antibody (1:5000) for 1 h at room temperature. Protein bands were visualized using a HyGLO™ Chemiluminescent HRP Antibody Detection Reagent (Denville Scientific, NJ) and exposed to X-ray film (Kodak, Rochester, NY). Densitometric analysis of resolved proteins was performed to quantify protein band intensity with AlphaEaseFC™ Software, version 4.0.1 (Alpha Innotech, San Leandro, CA).
Genomic DNA isolation and methylation-specific polymerase chain assay (MS-PCR)
Genomic DNA was isolated using QIAGEN Genomic DNA purification kit (QAIGEN, Valencia, CA). For bisulfite treatment, EZ DNA methylation™ kit was used. Briefly, a total of 500 ng genomic DNA (50 μl) was incubated with 100 μl of CT conversion buffer followed by incubation in a thermal cycler at 50 °C for 12 h. The DNA was purified by using Zymo-spin™ IC column and eluted in 10 μl of elution buffer according to the user manual. After DNA purification, the methylated genomic DNA was subjected to PCR amplification. An MS-PCR assay was performed in a total volume of 20 μl by using SeqAMP DNA poly-merase (Takara, Mountain View, CA) as per user manual. The oligonucleotide sequences used for the MSP were: mouse PTEN U forward: 5′-TTGGAGTATTGATTAAGGTGG-3′; mouse PTEN U reverse: 5′-CAAT ATATCCACAACTCACTCCC-3′; mouse PTEN M forward: 5′-TTCGGAGT ATCGATTAAGGC-3′; mouse PTEN M reverse: 5′-AATATATCCGCGACT CGCTC-3′; human PTEN U forward: 5′-AATTGATTTGGAGTTTGAGG-3′; human PTEN U reverse: 5′-AAAACTCTCAACCAAACATACTAAAC ATA-3′; human PTEN M forward: 5′-GAATCGATTTGGAGTTCGAG-3′; human PTEN M reverse: CTCAACCGAACGTACTAAACGTAA-3′. The PCR product was resolved on a 1.4% agarose gel.
Production of shRNA lentiviral particle and LX-2 cells transduction
Bacterial stocks plasmids encoding sh-DNMT3B, sh-PTEN (Cat. #TRCN0000437183 and TRCN0000002747), non-targeting shRNA (pLKO.1), PCD/NL-BH4 packaging and pLTR-G envelop plasmids were purchased from Sigma-Aldrich (St. Louis, MO). Production of shRNA lentivirus and transduction of cell lines were carried out as described previously [34] . LX-2 cells were transduced with concentrated and purified lentiviral particles (MOI = 5) in the presence of polybrene (5 μg/ml). The infected cells were cultured in complete growth medium for 72 h, and stable clones were selected with puromycin dihydrochloride (10 μg/ml). Survived colonies were pooled and expanded in complete cell culture medium containing puromycin (2 μg/ml) for further experiment.
Statistical analyses
All data are expressed as the mean ± standard error (SE) from 3 to 4 separate experiments. The differences between groups were analyzed using a two-tailed Student t-test when only two groups were analyzed or analysis of variance (ANOVA) when there were more than two groups were analyzed. The statistical analyses were conducted using the Excel (Microsoft office 2015), Graph-Pad Prism software version 5.04 (GraphPad® Software, San Diego CA). A P value < 0.05 was considered as statistically significant differences.
Results
Adiponectin attenuates liver fibrosis in CCl 4 -treated mice and modulates PTEN expression in WT mice.
In order to examine the role of adiponectin in PTEN expression, we utilized eight-week-old WT C57BL/6 J mice treated with CCl 4 for 6 weeks to induce liver fibrosis. We also administered recombinant-deficient adenovirus carrying cDNA of adiponectin (Ad-Adipo), and control adenovirus (Ad-LacZ) at week 4 for 2 weeks. Adiponectin levels were monitored by serum ELISA. Adiponectin delivery significantly increased serum adiponectin (Saline 9.8 ± 2.7 μg/ml; CCl 4 + Ad-LacZ 8.8 ± 3.4 μg/ml; CCl 4 + Ad-Adipo 18.2 ± 3.8 μg/ ml). Carbon tetrachloride (CCl 4 ) gavaged mice resulted in prominent liver injury including hepatocyte ballooning, steatosis, necrosis, and irregular liver lobule structure relative to normal liver (Fig. 1A) . However, adiponectin treatment improved the pathological changes in livers as assessed by H&E and Sirius red staining (Fig. 1A, B ). Fig. 1C -D shows that adiponectin treatment resulted in both reduction of serum transaminase levels and hepatic hydroxyproline content. PTEN mRNA and protein expression were significantly reduced (~0.5 fold compared to control) in the fibrotic liver, whereas combined adiponectin and CCl 4 treatment increased PTEN expression to levels comparable to control mice ( Fig. 2A, B , C, D, E). These data indicate that adiponectin treatment enhanced PTEN expression and reduced liver fibrosis.
Adiponectin treatment promotes PTEN expression in LX-2 cells
Because HSCs are primary regulators/mediators of liver fibrogenesis [35, 36] , we questioned whether adiponectin treatment upregulates PTEN expression specifically within this cellular subset. To address this hypothesis, we used a well-characterized immortalized human HSC cell line (LX-2). As anticipated, TGFβ1 (5 ng/ml) significantly decreased PTEN expression in vitro ( Fig. 3A; 0 .53 ± 0.12 fold change vs control) while co-treatment with high molecular weight recombinant adiponectin (10 μg/ml) prevented this effect ( Fig. 3A; 1.20 ± 0.11 fold change vs 0.53 ± 0.12 TGFβ1 treated cells). Moreover, adiponectin treatment also attenuated TGFβ1-induced α-SMA and collagen I (Fig. 3A, B ). However, while adiponectin treatment alone resulted in an increasing trend in PTEN expression, this observation failed to reach statistical significance (Fig. 3A, B ). Next, we employed sh-RNAmediated knockdown of PTEN (nearly 50% PTEN knockdown compared to scrambled sh-RNA pLKO.1) and treated the cells with TGFβ1 for 30 min, followed by Western blot analysis. TGFβ1 treatment induced AKT phosphorylation in control sh-pLKO.1-treated cells (Fig. 4A; 2 .51 ± 0.12 fold change vs control) while AKT was phosphorylated in PTEN knockdown LX-2 cells in both the presence and absence of TGFβ1 ( Fig. 4A ; ~ > 2 fold change in sh-PTEN knockdown cells with or without TGFβ1 vs sh-pLKO.1 control). Since AKT phosphorylation is directly linked to cell survival and activation of α-SMA in HSCs [37] [38] [39] . We performed cell proliferation assays to determine whether knockdown of PTEN induced cell proliferation in LX-2 cells. We found that knockdown of PTEN promotes LX-2 cell proliferation compared to sh-pLKO.1 (Fig. 4C; 1 .72 ± 0.18 mean optical density vs sh-pLKO.1 1.13 ± 0.12).
Adiponectin treatment attenuates DNMT3B expression and PTEN promoter methylation in vivo and in vitro
Previous studies have shown that PTEN promoter methylation can directly reduce PTEN expression in HSCs [20, 22, 31] . We examined DNMT expression in mouse liver by Western blot and qRT-PCR, and found that DNMT1, DNMT3A, and DNMT3B expression was significantly increased in CCl 4 -treated fibrotic liver ( Fig. 5A ; ~4 fold change vs controls). Adiponectin treatment, however, caused a significant reduction of DNMT3B expression in liver lysate (Fig. 5A, B , C; protein expression 1.26 ± 0.28 in CCl 4 + Ad-adipo fold change vs 8.62 ± 0.95 CCl 4 + Ad-LacZ; mRNA expression 2.66 ± 1.08 in CCl 4 + Ad-adipo fold change vs 8.62 ± 0.95 CCl 4 + Ad-LacZ). As anticipated, CCl 4 -treatment induced PTEN promoter methylation, and adiponectin treatment reduced PTEN methylation to levels comparable to control mice (Fig. 5D ). Similarly, in vitro data suggest that only DNMT3B expression was significantly reduced in the presence of adiponectin (Fig. 6A, B ). Adiponectin treatment reduced PTEN promoter methylation in LX-2 cells (Fig. 6C) . Culture-activated primary rat HSCs were also found to highly express all forms of DNMTs compared to freshly isolated, quiescent HSCs (Fig. 7) .
DNMT3B knockdown promotes PTEN expression in LX-2 cells
Our data indicate that TGFβ1-induced DNMT3B upregulation was significantly reduced by adiponectin; hence, we performed knockdown studies of DNMT3B via sh-RNA-mediated lentiviral vector (Fig. 8A, B ; 0.17 ± 0.09 fold change DNMT3B expression in sh-DNMT3B vs sh-pLKO.1). The sh-RNA mediated DNMT3B knockdown significantly induced PTEN expression compared to sh-pLKO.1 (Fig. 8A; 1 .39 + 0.10 fold change vs sh-pLKO.1). Interestingly, TGFβ1 failed to induce collagen type I and α-SMA expression in DNMT3B knockdown LX-2 cells compared to pLKO.1 LX-2 cells (Fig. 8A, B) .
The results revealed that expression of miR-29b significantly increased in adiponectintreated LX-2 cells compared to control ( Fig. 9A; 3 .70 ± 0.31 fold change vs control). We further investigated the effects of miR-29b inhibitors and mimic on DNMT3B and PTEN expression in LX-2 cells. Transfection with a miR-29b inhibitor significantly induced DNMT3B (Fig. 9B, D; 2.72 ± 0.12 fold change vs control) and α-SMA protein expression in LX-2 cells compared to the controls (Fig. 9B, D; 2.95 ± 0.22 fold change vs control), whereas PTEN expression was markedly reduced (Fig. 9B, D; 0.45 ± 0.07 fold change vs control). Conversely, transfection with a miR-29b mimic significantly up-regulated PTEN expression in LX-2 cells compared to controls (Fig. 9C, E; 1 .73 ± 0.17 fold change vs control), whereas DNMT3B (Fig. 9C, E; 0.51 ± 0.07 fold change vs control) and α-SMA were reduced (Fig. 9C, E; 0.36 ± 0.06 fold change vs control). These results suggest that adiponectin treatment upregulates miR-29b expression and in turn prevent DNMT3B expression in LX-2 cells. Ultimately, this process prevents PTEN downregulation and prohibits the fibrogenic response.
Discussion
Targeting specific molecules to combat liver fibrosis is a growing challenge in translational medicine. Significant progress has been made to elucidate molecular mechanisms related to liver fibrosis, and we now have a far better understanding of liver myofibroblast biology. While the anti-fibrotic properties of adiponectin have been well-characterized in preclinical settings [6, 7, 42, 43] , recombinant adiponectin therapy is not practical to administer to humans. Here, we investigated the potential role of adiponectin as an activator of PTEN expression that could reverse hepatic fibrosis. We report the following new observations: (i) Adiponectin treatment inhibits DNMT3B expression in vivo and in vitro; (ii) Adiponectin treatment reduced PTEN promoter methylation; (iii) Knockdown of PTEN results in hyperactivation of α-SMA: a key marker for HSCs activation; (iv) Knockdown of DNMT3B reduced α-SMA and collagen expression in HSCs; and (v) Adiponectin stimulation induced miR-29b and this increased PTEN expression. Together, our results provide a molecular explanation for a novel pathway that attenuates liver fibrosis through modulation of PTEN expression (Fig. 10) .
The role of PTEN in liver fibrosis has been well documented [19, 31, 44, 45] . PTEN can dephosphorylate PIP3 to PIP2, which can antagonize the PI3kinase signaling pathway. Reduced PTEN expression leads to PIP3 accumulation resulting in activation of PI3kinase followed by phosphorylation of AKT. AKT is a pro-cell survival protein that is well documented for its role in HSC proliferation and migration [13, 46] . A recent report suggests that PTEN overexpression by adenovirus in the CCl 4 -induced rat liver fibrosis model reduced serum ALT and AST while decreasing collagen deposition in the liver [47] . Here, we report that adiponectin can prevent the loss of PTEN during CCl 4 -induced liver fibrosis and in activated HSCs. In contrast to our observations, adiponectin treatment transiently reduced PTEN expression in human bone marrow-derived stromal cells (hBMSC), indeed adiponectin-treatment partially induced PTEN expression in hBMSC after 2 h of treatment [48] . A possible explanation for this discrepancy could be that adiponectin PTEN expression in a time-dependent manner. PTEN expression can be regulated through several mechanisms such as promoter methylation, gene mutation, and via post-translational modifications including phosphorylation at its C-terminus. In the current study, we saw no changes in PTEN phosphorylation status in the presence or absence of adiponectin (data not shown); however, adiponectin treatment did alter the status of PTEN promoter methylation both in vivo and in vitro.
We and others have previously shown that adiponectin exerts its beneficial effects on liver fibrosis via several signaling pathways including the phosphorylation of 5′ adenosine monophosphate-activated protein kinase (AMPK), focal adhesion kinase (FAK), Sirtuin 1 (SIRT1), protein tyrosine phosphatase 1B (PTP1B), suppressor of cytokine signaling-3 (SOCS-3), and the peroxisome proliferator-activated receptor-(PPARα) [7, 8, 49, 50] . Recently published studies have clarified the role of miRNAs in liver fibrosis [29, 30, 44] . Not surprisingly, miRNAs have been shown to play both an anti-fibrogenic and a profibrogenic role depending on the genes targeted and the nature of the stimulus [20] [21] [22] 31, 32] . Here, we showed that adiponectin up-regulates miR-29b expression in LX-2 cells. Moreover, overexpression of miRNA-29b increased PTEN levels in LX-2 cells; conversely, the miR-29b inhibitor suppressed PTEN expression. DNMT3B levels were increased LX-2 cells transfected with a miR-29b inhibitor, whereas DNMT3B expression was reduced in LX-2 transfected with a miR-29b mimic RNA. Our data suggest the presence of a novel adiponectin/miR-29B/DNMT3B/PTEN signaling pathway. It has been recently reported that miR-29b/142-5p overexpression inhibits DNMTs expression in biliary atresia and contributes to pathogenesis by regulating interferon γ (IFN γ) [51] . Moreover, miR-29b overexpression results in decreased overall gene methylation and overexpression of IFN γ [51] .
In conclusion, these studies provide novel insights for another molecular mechanism whereby adiponectin plays a very important role in attenuation of liver fibrosis via upregulation of miR-29b expression in LX-2 cells. Targeting activated HSCs is an emerging strategy for the prevention of liver fibrosis, which could lead to new anti-fibrotic treatment strategies that could eventually come to the clinic. 
